Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27411133 | 0.86 | HRH3 (0.56) | SLC6A4SLC6A2OPRM1OPRD1OPRK1 | |
| SCHEMBL14593440 | 0.80 | SLC6A4 (0.57) | SLC6A4SLC6A2TACR1SLC6A3 | |
| SCHEMBL11625461 | 0.80 | HRH3 (0.58) | SLC6A4SLC6A2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL3953529 | 0.77 | SLC6A4 (0.54) | SLC6A4SLC6A2TACR1SLC6A3 | |
| SCHEMBL11620858 | 0.76 | HRH3 (0.53) | SLC6A4SLC6A2OPRM1OPRD1OPRK1 | |
| SCHEMBL7101455 | 0.75 | CYP2D6 (0.64) | SLC6A4SLC6A2OPRM1OPRD1OPRK1 | |
| SCHEMBL13974437 | 0.75 | HRH3 (0.51) | SLC6A4SLC6A2OPRM1OPRD1OPRK1 | |
| SCHEMBL10413788 | 0.74 | SLC6A4 (0.69) | SLC6A4SLC6A2OPRM1OPRD1OPRK1 | |
| SCHEMBL5444519 | 0.73 | SLC6A4 (0.76) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4732656 | 0.73 | SLC6A2 (0.58) | SLC6A4SLC6A2TACR1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895558-B2 | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | GREEN CROSS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| WO-2010038948-A2 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | NPY5R, TPH2, MC5R | SLC6A4 111/4885SLC6A2 171/4885OPRM1 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.